Group items tagged

Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.

The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price. The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel disease and psoriasis, has accounted for about one third of the savings. After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions, which have the same quality, safety and efficacy of a branded one. Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to aggressive blood cancers. Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality patient care. NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.

The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations. A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023. Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway. "We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."

Dr Michael Gamlen, the inventor of Gamlen instruments presents a tablet press machine to the students at the School of Pharmacy on 16 October. The equipment not only solves the challenge of producing lab-scale tablets under precise conditions but also offers valuable insights into material compaction properties. It is also known as a powder compaction analyser which has been given on loan to the University of Sunderland for five years. Dr Gamlen talks about the machine and how pharmacy students will benefit, saying: "It allows you to make tablets under tightly controlled conditions and enables you to make accurate comparisons between different materials and processes. "The students will be able to easily see the impact of the tablet compaction conditions on tablet properties. This is very important to understand when developing new tablet formulations and manufacturing products."

The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission. UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week. The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI." It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments effectively. Henceforth, it will provide us with better data on how well new therapies work. Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."

Global instant logistics leader, Zipline is partnering with UK drone delivery startup, Apian Aero to launch a drone delivery programme of critical medical supplies for the Northumbria Healthcare NHS Foundation Trust. The new service, expected to begin in the autumn of 2024, will see delivery of medical supplies to hospitals, GPs and care homes, using electric, autonomous drones. Zipline announced the partnership on Sunday, and said drone delivery service will help provide timely access to prescription medicines, wound care products, joint replacement implants, and other frequently ordered medical products, which could allow healthcare providers to reduce the number of cancelled procedures, and thus decrease wait times. Also, the expansion of the programme will help in creating local job opportunities in the region, it added.

Hi friends,good afternoon ,today i will attempt to post an important information regarding vitamin B12[cobalamin] and it's deficiency in strictly vegetarian diets.

Vitamin B12 helps keep the body's nerve and blood cells healthy. Also, it helps prevent a type of anemia that makes people tired and weak. You can find out more about it on the Canadian pharmacy site https://www.canadapharmacy.com/. I take it daily. But I recommend addressing a doctor first.

If you're looking for the perfect spot to enjoy some truly memorable seafood in NYC, I can't recommend this place enough. The ambiance is incredible, with a stunning view of the Hudson that makes every visit feel special. The seafood here is top-notch-fresh, flavorful, and cooked to perfection. Whether you're in the mood for some classic oysters or something more adventurous, the menu has something for everyone. And it's not just the food; the service is exceptional too. The staff are friendly, knowledgeable, and really make you feel welcome. It's the kind of place where you can sit back, relax, and enjoy a great meal with friends or family. If you're planning a special occasion or just want to treat yourself to a nice dinner out, this spot should definitely be on your list. Trust me, once you've tried the https://pjclarkes.com/menu/on-the-hudson/, you'll be coming back for more.

The juice of Acai berry is consumed in many forms like smoothies,mix,soda,ice-cream etc.Regarding the use of various forms of acai as a weight loss supplement i could not find any controlled study.But this much i can say none of the aforementioned claims have been validated by the FDA.

Natural food coloring is in demand owing to their health benefits as well. The increased efforts in R&D are helping the major Companies to explore new areas of innovations for food colorant and its applications, providing additional growth opportunities. To know how the food coloring market is going to perform across the world. Read the report summary and Download sample report now @ http://bit.ly/36kZpje

US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory illnesses and help improve readiness for any future pandemics. The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement. Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris Johnson to reopen the economy from stringent lockdowns. Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV). "By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be pandemic ready," Bancel said on Wednesday.

Following centuries of stigma, the importance of mental wellness is finally matching that of physical healthcare. Conditions such as depression have become common topics in the media, particularly in the last few years as celebrities and experts warned against the pressures of social media. The bouts of isolation connected with the Covid-19 pandemic exacerbated the issue, with the British Medical Association declaring a UK mental health crisis at the end of 2022. This media attention has led to acknowledgement of the realities of mental health problems from the government and medical sector, and a recognition that these need to be approached differently to physical ailments when it comes to providing treatment. If you are motivated to be involved in this rapidly changing industry, consider these rewarding business ideas for developing a career in mental health. Become a counsellor Counselling is a broad term, but essentially it is the practice of having impartial conversation with patients about their life experiences with a view to overcoming emotional obstacles and trauma. Training can take three to five years depending on whether you are getting a degree or diploma, and there are many opportunities to specialise both during and after your education. Psychotherapy is a similar field, but this is a more academically focused course that tends to be concerned with long-term or particularly complex mental health issues. You will need a post-graduate qualification and several years of training to become certified.

The Pharmacists Defence Association (PDA) has welcomed the government's action of publishing 'AI Regulation White Paper' which will regulate the artificial intelligence (AI) system used in pharmacy on Wednesday (29 March). The Association had raised concerns about the risk of patient harm due to inappropriate use of so-called AI to include that seen in some of the pharmacy systems undertaking clinical checks. For some time, it has been receiving concerns from practicing pharmacists describing examples of the potentially detrimental impact of automation and online pharmacy provision on patient safety and pharmacy practice. As a result, it raised these concerns with regulators, Chief Pharmaceutical Officers, and parliamentarians in all four nations of the UK to urge action. It said: "This is required not only to protect patients, but also the frontline pharmacists who could be blamed for potential harm caused by inappropriate use of so called 'AI' systems implemented by their employer." The PDA therefore, welcomes the announcement from the UK government that they intend to strengthen regulation of such technology, empowering existing regulators to come up with tailored, context-specific approaches that suit the way AI is actually being used in their sectors; this will include pharmacy.

Find diet information and resources on the best fitness diet plans, diet plans and fitness plans.

Dr Syeda Batool Mazhar is very Expert to Deal with OBS and GYN Patients Dr. Syeda Batool is an alum of King Edward Medical College Lahore. She did her Specialization (FCPS) in Obs and Gyne in 2010 from The College of Phys and Surgeon Pakistan. She is also Member of the Royal College of OBS and GYN U.K. She has done her FRCOG, Fellow of the Royal College of OBS and GYN, U.K in 2005.At Present she is filling in as Dean of Nursing and Allied staff, SZABMU, since2016. Additionally she is Co-Chairperson RWP/ISB Chapter, Society of OBGYN, Pak since 2016. She is Chairperson OBGYN MCH Center, PIMS, SZABMU, Islamabad, since 2012. She was also Member of World Health Orignization (WHO) guiding council for examine on Madication-assisted Treatment (Mat) Health.she is likewise filling in as Consultant Gynecologist and Infertility Specialist at Australian Concept Infertility Medical Center Islamabad . Her uncommon advantages are Safe Motherhood, menopause and Infertility medicines.Dr Syeda Batool Mazhar Private Clinic is F8/3 Islamabad. https://fitnessfiestapro.blogspot.com/2020/03/pro-dr-syeda-batool-mazhar-consultant.html

Small Intestinal Bacterial Overgrowth (SIBO): Identification, Treatment and Prevention is organized by Dietitian Central. For More Info: https://www.emedevents.com/online-cme-courses/webcasts/small-intestinal-bacterial-overgrowth-sibo-identification-treatment-and-prevention

FlowForce Max is an innovative, natural and effective way to address your prostate problems, while adding your energy, libido, and vitality. An impeccably cured personal mix of precisely named plants and minerals, crafted and mixed to complement one another into an important prostate supporting formula. Produced in FDA- approved, GMP- certified installations, each bottle of this nutritive supplement comes with 30 tablets. So, if you follow the instructions given by the manufacturers, it also claims to be an each-natural, GMO-free supplement.

Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead manufacturing site in the UK. This decision will impact 435 employees and comes as part of a broader strategic realignment of the company's global manufacturing operations according to BBC. The Maidenhead facility, which has been in operation for years, manufactures some of Haleon's most popular oral health products, including Sensodyne and Parodontax. However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable. In a statement issued by a spokesperson for Haleon, they stated, "Following a strategic review of our global manufacturing capabilities, we have determined that our Maidenhead site is no longer a viable option for the manufacture of our products."

This event provides an excellent opportunity for companies and organizations to showcase their products, services, and expertise to an engaged audience of pediatric neurologists and healthcare professionals.

Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.

A full CPE Committee Meeting was organised in London on April 17 and 18, 2024, to discuss crucial sectoral issues. Key topics discussed during the two-day meeting included intolerable pressures on pharmacy owners, the ongoing Community Pharmacy Contractual Framework (CPCF) negotiations, implementation of the Pharmacy First service, and governance changes. Committee Members reviewed the progress of CPCF negotiations with the Department of Health and Social Care (DHSC) and NHS England. These critical negotiations are being led by the Negotiating Team (NT), which includes independent pharmacy owners and representatives of CCA and non-CCA multiples. The CPE has been advocating for an uplift to the core global sum, margin write-offs, an agreed mechanism for regular funding increases linked to activity and inflation, annual uplifts to service fees, more fundamental reform of the margin delivery framework and an economic review of the medicines supply chain. The Committee also discussed the results of the 2024 Pharmacy Pressures Survey, which was conducted during March and April.

Matthew Taylor, Chief Executive of the NHS Confederation, delivered a compelling speech at the NHS ConfedExpo 2024, emphasising the critical need for investment in community-based care and the revitalisation of primary care services. In his address, Taylor also criticised the current health policy as "not fit for purpose," calling for radical changes to shift the NHS from a reactive to a proactive health model. Addressing delegates at the Manchester event, Taylor highlighted the importance of shifting resources towards prevention and community services. Underscoring a strategic pivot from reactive to proactive health models, he said: "We must see action to fulfil the long-held vision of a health service that invests better upstream in prevention, in primary and in community-based care."